Study guide

4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management

Medical Council of Canada Qualifying Examination Part I MCCQE Part I

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice

1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics

2 Chapter 2: Population Health, Health Promotion & Preventive Care

2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada

3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems

3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions

4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology

4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers

5 Chapter 5: General Surgery, Orthopedics, & Emergency Care

5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition

6 Chapter 6: Pediatrics & Adolescent Health

6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management

7 Chapter 7: Obstetrics & Gynecology

7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation

8 Chapter 8: Psychiatry & Mental Health

8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)

9 Chapter 9: Neurology, Rheumatology, & Dermatology

9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine

10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice

10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety

4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management

Key Takeaways Explain This Topic AI

Diabetes Canada criteria diagnose diabetes with FPG ≥ 7.0 mmol/L, 2h 75g OGTT ≥ 11.1 mmol/L, HbA1c ≥ 6.5%, or random plasma glucose ≥ 11.1 mmol/L with classic symptoms.

Standard HbA1c target is ≤ 7.0% for most adults; individualized targets range from ≤ 6.5% (for microvascular protection in low-hypoglycemia-risk patients) to 7.1%–8.5% (in frail elderly or those with severe hypoglycemia history).

In patients with T2D and established ASCVD, CKD (eGFR 20–60 mL/min/1.73m² or UACR > 3 mg/mmol), or Heart Failure, SGLT2 inhibitors or GLP-1 receptor agonists are indicated with proven cardiorenal benefit INDEPENDENT of baseline HbA1c.

Emergency DKA management requires IV Normal Saline resuscitation, checking serum potassium BEFORE insulin initiation (hold insulin if K+ < 3.3 mmol/L), IV regular insulin infusion (0.1 units/kg/h), and adding D5W when glucose reaches 14.0 mmol/L.

SGLT2 inhibitor therapy can precipitate euglycemic DKA (blood glucose < 11.1 mmol/L with high anion gap metabolic acidosis and ketonemia), requiring immediate SGLT2i cessation and standard DKA protocol.

Last updated: July 2026

  • 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management
  • Diagnostic Criteria & Screening Guidelines

According to Diabetes Canada Clinical Practice Guidelines , screening for Type 2 Diabetes (T2D) should be performed every 3 years in all adults aged ≥ 40 years , or more frequently in individuals with risk factors (e.g., first-degree relative with T2D, high-risk ethnicity, metabolic syndrome, history of gestational diabetes, or corticosteroid use).

Diagnostic Thresholds Table

  • Diagnostic Test Normal Prediabetes Diabetes Mellitus
  • Fasting Plasma Glucose (FPG) < 5.6 mmol/L 5.6 – 6.9 mmol/L (Impaired Fasting Glucose) ≥ 7.0 mmol/L
  • 2-Hour 75g OGTT < 7.8 mmol/L 7.8 – 11.0 mmol/L (Impaired Glucose Tolerance) ≥ 11.1 mmol/L
  • Glycated Hemoglobin (HbA1c) < 5.7% 6.0 – 6.4% (High Risk for Diabetes) ≥ 6.5%
  • Random Plasma Glucose N/A N/A ≥ 11.1 mmol/L (with symptoms)

Note : In the absence of symptomatic hyperglycemia (polyuria, polydipsia, weight loss), a single abnormal laboratory result must be confirmed by repeat testing on a separate day.

Individualized Glycemic Targets

Diabetes Canada emphasizes individualized HbA1c targets based on patient characteristics:

HbA1c ≤ 7.0% : Standard target for most non-pregnant adults with Type 1 or Type 2 Diabetes to reduce microvascular (retinopathy, nephropathy, neuropathy) and macrovascular complications.

HbA1c ≤ 6.5% : Recommended in select newly diagnosed patients with long life expectancy, low hypoglycemia risk, and absence of cardiovascular disease, to achieve long-term microvascular risk reduction.

HbA1c 7.1% – 8.5% : Individualized target for patients with:

Severe hypoglycemia history or hypoglycemia unawareness.

Limited life expectancy.

Advanced microvascular or macrovascular disease.

Frail elderly status or high functional dependency.

Glycemic Range Targets : Fasting/preprandial glucose 4.0 – 7.0 mmol/L ; 2-hour postprandial glucose 5.0 – 10.0 mmol/L (5.0 – 8.0 mmol/L if HbA1c target is ≤6.5%).

Pharmacotherapy & Organ-Protection Framework

First-line therapy for all patients with T2D includes healthy behavior interventions (dietary optimization, exercise) combined with Metformin (unless contraindicated, e.g., eGFR < 30 mL/min/1.73m² due to lactic acidosis risk).

The Cardiorenal Paradigm Shift

Regardless of baseline HbA1c or current metformin use, Diabetes Canada guidelines mandate evaluating for clinical cardiorenal conditions and initiating organ-protective agents immediately:

Established ASCVD (prior MI, stroke, PAD): Add an SGLT2 inhibitor (Empagliflozin, Dapagliflozin, Canagliflozin) OR a GLP-1 receptor agonist (Semaglutide, Liraglutide, Dulaglutide) with proven cardiovascular outcome reduction.

Heart Failure (HFrEF or HFpEF): Add an SGLT2 inhibitor (Empagliflozin, Dapagliflozin) to reduce heart failure hospitalizations and CV mortality.

Chronic Kidney Disease (eGFR 20–60 mL/min/1.73m² or UACR > 3.0 mg/mmol): Add an SGLT2 inhibitor (Empagliflozin, Dapagliflozin, Canagliflozin) to slow CKD progression, reduce ESKD, and lower CV mortality.

Antihyperglycemic Class Comparison

  • Class & Examples Hypoglycemia Risk Weight Impact Cardiorenal Benefit Key Clinical Considerations
  • Metformin Negligible Neutral / Loss Moderate CV safety First-line; stop if eGFR < 30 mL/min/1.73m²

SGLT2 Inhibitors ; (Empagliflozin, Dapagliflozin) Negligible Loss (2-3 kg) Decreased HF hospitalization, decreased CKD progression, decreased CV death Mycotic genital infections, volume depletion, Euglycemic DKA

GLP-1 RAs ; (Semaglutide, Liraglutide) Negligible Significant Loss Decreased MACE, stroke, CV death Nausea/vomiting; avoid in personal/family history of MTC / MEN 2

DPP-4 Inhibitors ; (Sitagliptin, Linagliptin) Negligible Neutral Neutral Saxagliptin increases HF risk; Linagliptin requires no renal dose adjustment

Sulfonylureas ; (Gliclazide, Glyburide) Moderate – High Gain Neutral High hypoglycemia risk ; Gliclazide MR preferred over glyburide

Insulin ; (Glargine, Degludec, Aspart) High Gain Neutral Indicated if severe hyperglycemia (HbA1c ≥ 1.5% above target) or symptomatic

Acute Metabolic Emergencies: DKA vs HHS

  • Feature Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)
  • Primary Population Type 1 Diabetes (primarily) Type 2 Diabetes (elderly, dehydrated, infection)
  • Serum Glucose > 14.0 mmol/L (or normal in Euglycemic DKA) > 30.0 mmol/L
  • Arterial / Venous pH < 7.30 (Severe < 7.00) > 7.30
  • Serum Bicarbonate < 18 mmol/L > 18 mmol/L
  • Anion Gap Elevated (> 10–12 mmol/L) Normal or mildly elevated
  • Serum Ketones Strongly Positive (Beta-hydroxybutyrate > 3.0 mmol/L) Absent or trace
  • Serum Osmolality Variable Markedly Elevated (> 320 mOsm/kg)
  • Step-by-Step DKA Management Protocol

Fluid Resuscitation : Administer 0.9% Normal Saline 1.0–1.5 L IV in the 1st hour . Switch to 0.45% NaCl if corrected serum sodium is normal or elevated.

Potassium Check (CRITICAL) : Check K+ BEFORE initiating IV insulin!

K+ < 3.3 mmol/L : HOLD insulin! Administer IV KCl 20–30 mEq/h until K+ > 3.3 mmol/L to prevent fatal arrhythmias.

K+ 3.3–5.0 mmol/L : Give regular insulin AND add 20–30 mEq KCl per liter of IV fluid to maintain serum K+ 4.0–5.0 mmol/L.

K+ > 5.0 mmol/L : Initiate IV insulin infusion; monitor serum K+ every 1–2 hours without adding potassium to IV fluids.

Insulin Infusion : Administer regular insulin IV at 0.1 units/kg/h . Target a steady glucose drop of 3.0–4.0 mmol/L per hour.

Addition of Dextrose : When serum glucose reaches 14.0 mmol/L , add 5% Dextrose (D5W) to IV fluids while CONTINUING insulin infusion at 0.05–0.1 units/kg/h. Continue IV insulin until the anion gap closes (< 10–12 mmol/L), bicarbonate is ≥ 18 mmol/L, and pH > 7.30.

Inpatient Glycemic Control & Complication Screening

Inpatient Targets : Non-critical ward patients target preprandial glucose 6.0–8.0 mmol/L and random glucose < 10.0 mmol/L. Sliding-scale insulin monotherapy is ineffective and strongly discouraged. Use a structured Basal-Bolus-Correction insulin regimen.

Annual Complication Screening :

Nephropathy : Annual Urine Albumin-to-Creatinine Ratio (UACR) plus eGFR. Normal UACR < 2.0 mg/mmol; Microalbuminuria 2.0–20.0 mg/mmol; Overt nephropathy > 20.0 mg/mmol.

Retinopathy : Dilated eye examination every 1–2 years.

Neuropathy : 10-g Semmes-Weinstein monofilament test annually.

Cardiovascular Statin Indication : Statin therapy is indicated for all adults with diabetes who are age ≥ 40 , OR have established cardiovascular disease, OR have microvascular disease, regardless of baseline LDL-C (target LDL-C < 2.0 mmol/L).

Warning

MCCQE1 High-Yield Trap: Euglycemic DKA with SGLT2 Inhibitors SGLT2 inhibitors (empagliflozin, dapagliflozin) can trigger Euglycemic DKA during times of physiological stress, surgery, acute infection, or carbohydrate restriction. Serum glucose is characteristically < 11.1 mmol/L (often 7.0–10.0 mmol/L), masking the diagnosis! Key features: High anion gap metabolic acidosis with positive serum beta-hydroxybutyrate. Management: Stop SGLT2i immediately, administer IV fluids, IV regular insulin, AND IV dextrose (D5W) simultaneously.

Loading diagram... Diabetes Canada T2D Pharmacotherapy & Cardiorenal Protection Decision Tree